Original Article

You have free access to this content

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily†‡

Two-year follow-up of a randomized phase 2 study (START-R)

  1. Hagop Kantarjian MD1,§,*,
  2. Ricardo Pasquini MD2,
  3. Vincent Lévy MD, PhD3,
  4. Saengsuree Jootar MD4,
  5. Jerzy Holowiecki MD, PhD5,
  6. Nelson Hamerschlak MD, PhD6,
  7. Timothy Hughes MD7,
  8. Eric Bleickardt MD8,
  9. David Dejardin MSc8,
  10. Jorge Cortes MD1,
  11. Neil P. Shah MD, PhD9

Article first published online: 17 JUN 2009

DOI: 10.1002/cncr.24504

Issue

Cancer

Cancer

Volume 115, Issue 18, pages 4136–4147, 15 September 2009

Additional Information

How to Cite

Kantarjian, H., Pasquini, R., Lévy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., Hughes, T., Bleickardt, E., Dejardin, D., Cortes, J. and Shah, N. P. (2009), Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. Cancer, 115: 4136–4147. doi: 10.1002/cncr.24504

Author Information

  1. 1

    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Hospital De Clinicas De Curitiba, Parana, Brazil

  3. 3

    Clinical Investigation Center, AP-HP, INSERM U9504, Hôpital Saint-Louis, Paris, France

  4. 4

    Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

  5. 5

    University Hospital-SPSKM, Katowice, Poland

  6. 6

    Hospital Israelita Albert Einstein, Sao Paulo, Brazil

  7. 7

    Division of Hematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia

  8. 8

    Bristol-Myers Squibb, Wallingford, Connecticut

  9. 9

    Division of Hematology and Oncology, University of California at San Francisco School of Medicine, San Francisco, California

  1. §

    Fax: (713) 794-4297

*Department of Leukemia, Unit 428, The University of Texas M. D. Anderson Cancer Center, PO Box 301402, Houston, TX 77230-1402

  1. †

    Presented previously in part as an oral presentation at the 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, Georgia, December 8-11, 2007; and as a poster presentation at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 30 to June 3, 2008; and at the 13th Congress of the European Hematology Association, Copenhagen, Denmark, June 12-15, 2008.

  2. ‡

    The following principal investigators, in addition to the authors, also participated in the CA180-017 study: J. J. Garcia, I. Otero, and D. Riveros (Argentina); C. Arthur (Australia); A. Bosly and W. Schroyens (Belgium); P. E. Dorlhiac Llacer and A. Moellman Coelho (Brazil); S. Assouline, D. Forrest, C. Gambacorti-Passerini, P. Laneuville, and A. Turner (Canada); M. Varik (Estonia); K. Porkka (Finland); T. Facon, F. Guilhot, M. Michalet, J. Reiffers, and P. Rousselot (France); C. Bokemeyer, A. Hochhaus, and D. Niederwieser (Germany); T. Masszi (Hungary); A. Nagler (Israel); D. W. Kim (Korea); H. Hjorth-Hansen (Norway); L. Casanova and J. Navarro (Peru); P. Caguioa (Philippines); A. Dmoszynska, W. Jedrzejczak, A. Hellmann, T. Robak, and A. Skotnicki (Poland); F. Cabanillas (Puerto Rico); N. Khoroshko, A. Zaritsky, and A. Golenkov (Russia); J. Lombard, P. Ruff, and G. Cohen (South Africa); L. Stenke and H. Wadenvik (Sweden); L. Y. Shih (Taiwan); J. Apperley, T. Holyoake, and S. O'Brien (United Kingdom); and J. Dipersio, J. K. Giguere, R. Lloyd, J. McGuirk, M. S. Murali, R. M. Stone, and R. Paquette (United States). In addition, K. Gialelis served as protocol manager, and A. Zhao and E. Cormier served as protocol data managers.

Publication History

  1. Issue published online: 4 SEP 2009
  2. Article first published online: 17 JUN 2009
  3. Manuscript Accepted: 10 FEB 2009
  4. Manuscript Received: 17 DEC 2008

Funded by

  • Bristol-Myers Squibb
  • Novartis
  • Wyeth

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (297K)

References

  • 1
    National Comprehensive Cancer Network, Inc. The Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology. Version 1.2009. Available at http://www.nccn.org. Accessed August 29, 2008.
  • 2
    Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108: 1809–1820.
  • 3
    O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994–1004.
  • 4
    Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007; 357: 258–265.
  • 5
    Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408–2417.
  • 6
    Hochhaus A, Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am. 2004; 18: 641–656.
  • 7
    Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003; 101: 473–475.
  • 8
    Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008; 111: 1039–1043.
  • 9
    Jabbour E, Kantarjian H, Atallah E, et al. Impact of imatinib mesylate dose escalation on resistance and suboptimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) [abstract]. Blood. 2007; 110: 313a–314a. Abstract 1035.
  • 10
    Kantarjian HM, Druker BJ, Guilhot F, et al. Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood. 2007; 110: 317a. Abstract 1047.
  • 11
    Marin D, Goldman JM, Olavarria E, et al. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood. 2003; 102: 2702–2703.
  • 12
    Zonder JA, Pemberton P, Brandt H, et al. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res. 2003; 9: 2092–2097.
  • 13
    O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005; 65: 4500–4505.
  • 14
    Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305: 399–401.
  • 15
    Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007; 109: 2303–2309.
  • 16
    Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008; 22: 1200–1206.
  • 17
    Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007; 109: 5143–5150.
  • 18
    Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008; 26: 3204–3212.
  • 19
    Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354: 2531–2541.
  • 20
    Mauro MJ, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol. 2008; 26: 374s. Abstract 7009.
  • 21
    Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349: 1423–1432.
  • 22
    Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108: 28–37.
  • 23
    Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934; 26: 404–413.
  • 24
    Agresti A, Min Y. On small-sample confidence intervals for parameters in discrete distributions. Biometrics. 2001; 57: 963–971.
    Direct Link:
  • 25
    Brookmyer R, Crowley JJ. A confidence interval for the median survival time. Biometrics. 1982; 38: 29–41.
  • 26
    Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997; 337: 223–229.
  • 27
    de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26: 3358–3363.
  • 28
    Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005; 105: 2640–2653.
View Full Article (HTML) Get PDF (297K)